PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-73.61%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
-74.78%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-74.78%
Both companies reducing total costs. Martin Whitman would check industry trends.
5.73%
Interest expense growth while RVPH reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
74.78%
EBITDA growth exceeding 1.5x RVPH's 5.85%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
74.78%
Operating income growth exceeding 1.5x RVPH's 7.11%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.85%
Tax expense reduction while RVPH shows 52.58% growth. Joel Greenblatt would examine advantage.
64.85%
Net income growth exceeding 1.5x RVPH's 5.90%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
64.71%
EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
64.71%
Diluted EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.